Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of AdaptHealth Corp (NASDAQ: AHCO) was $9.21 for the day, down -0.22% from the previous closing price of $9.23. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 0.81 million shares were traded. AHCO stock price reached its highest trading level at $9.28 during the session, while it also had its lowest trading level at $9.13.
Ratios:
Our analysis of AHCO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.39. For the most recent quarter (mrq), Quick Ratio is recorded 0.82 and its Current Ratio is at 1.06. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 1.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on January 08, 2024, Downgraded its rating to Hold and sets its target price to $8 from $14.50 previously.
On November 08, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $9.50 to $6.50.
Stifel Downgraded its Buy to Hold on May 10, 2023, whereas the target price for the stock was revised from $18 to $11.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 22 ’25 when Williams David Solomon III sold 8,200 shares for $9.73 per share. The transaction valued at 79,786 led to the insider holds 50,045 shares of the business.
Rietkerk Shaw bought 32,500 shares of AHCO for $315,250 on Dec 19 ’24. On Dec 10 ’24, another insider, Clemens Jason A, who serves as the Chief Financial Officer of the company, sold 35,000 shares for $9.35 each. As a result, the insider received 327,250 and left with 420,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AHCO now has a Market Capitalization of 1246094592 and an Enterprise Value of 3105663744. As of this moment, AdaptHealth’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.22, and their Forward P/E ratio for the next fiscal year is 8.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 0.78. Its current Enterprise Value per Revenue stands at 0.958 whereas that against EBITDA is 4.91.
Stock Price History:
The Beta on a monthly basis for AHCO is 1.59, which has changed by -0.18133336 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, AHCO has reached a high of $11.70, while it has fallen to a 52-week low of $7.11. The 50-Day Moving Average of the stock is -0.38%, while the 200-Day Moving Average is calculated to be -3.01%.
Shares Statistics:
AHCO traded an average of 1.26M shares per day over the past three months and 934660 shares per day over the past ten days. A total of 135.22M shares are outstanding, with a floating share count of 90.41M. Insiders hold about 33.18% of the company’s shares, while institutions hold 78.16% stake in the company. Shares short for AHCO as of 1753920000 were 10387889 with a Short Ratio of 8.23, compared to 1751241600 on 10172575. Therefore, it implies a Short% of Shares Outstanding of 10387889 and a Short% of Float of 10.03.
Earnings Estimates
AdaptHealth Corp (AHCO) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.44, with high estimates of $0.5 and low estimates of $0.37.
Analysts are recommending an EPS of between $0.94 and $0.69 for the fiscal current year, implying an average EPS of $0.81. EPS for the following year is $1.14, with 6.0 analysts recommending between $1.23 and $0.97.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $803.5M to a low estimate of $796.4M. As of the current estimate, AdaptHealth Corp’s year-ago sales were $805.86MFor the next quarter, 8 analysts are estimating revenue of $847.88M. There is a high estimate of $863.1M for the next quarter, whereas the lowest estimate is $840.14M.
A total of 8 analysts have provided revenue estimates for AHCO’s current fiscal year. The highest revenue estimate was $3.24B, while the lowest revenue estimate was $3.22B, resulting in an average revenue estimate of $3.23B. In the same quarter a year ago, actual revenue was $3.26BBased on 8 analysts’ estimates, the company’s revenue will be $3.45B in the next fiscal year. The high estimate is $3.59B and the low estimate is $3.34B.
